ZYBT: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Zhengye Biotechnology

The price history of Zhengye Biotechnology (ZYBT) demonstrates an EV/EBITDA multiple of 0.00, while the business relies on government support within the biotechnology sector. Zhengye Biotechnology (ZYBT) is implementing advanced veterinary solutions to ensure the protection of meat supplies and food stability. Primary revenue is generated through the creation of high-efficiency drugs and vaccines for swine and cattle breeding.

The EV/EBITDA multiple determines the business value relative to its operating profit before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA trajectory of Zhengye Biotechnology (ZYBT) on the GURU.Markets platform, an investor assesses the payback period of assets adjusted for net debt. This metric reveals the balance between debt load and production efficiency. For Zhengye Biotechnology (ZYBT), this is critical, as the robotization of vaccine bottling lines requires high capital expenditures that impact the overall enterprise value.